Project Grant K99HL188210
Award Date 9/1/26
Completion Date 5/31/28
Dollars Obligated $109K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Phoenix, AZ 85004, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $748,677 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop nanoparticle delivery systems targeting lung endothelial cell repair in pediatric acute respiratory distress syndrome (ARDS). The research addresses the lack of innovative molecular approaches to pediatric ARDS management by engineering lung endothelial cell-specific nanoparticle carriers capable of delivering...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $778,582 on August 15, 2026, to identify genetic variants that perturb gene regulatory responses to athero-protective and athero-prone hemodynamic waveforms in human endothelial cells. The award funds research under the Cardiovascular Diseases Research program (CFDA 93.837). The project investigates how natural genetic variation governs endothelial cell responses to hemodynamic shear stress from blood flow, with...
- The National Heart, Lung, and Blood Institute awarded The University of North Texas Health Science Center at Fort Worth $426,550 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a bioengineering modular gene delivery system for lung-targeted transgene expression. The project addresses systemic gene therapy for monogenic lung diseases including cystic fibrosis, alpha-1-antitrypsin deficiency, and pulmonary arterial hypertension. The recipient...
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $778,202 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research targeting inflammaging-induced endothelial injury and acute respiratory distress syndrome (ARDS) development in aging lungs. The research investigates how aging influences endothelial barrier injury mechanisms in ARDS, with focus on endothelial NADPH oxidase 2 (NOX2)...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $781,860 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the novel role of neutrophils in mediating endothelial regeneration and vascular repair in sepsis and acute respiratory distress syndrome (ARDS). The research addresses ARDS pathology, specifically endothelial barrier injury and increased vascular...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $670,622 as a Project Grant (R01HL180941) on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the role of endogenous RNA sensing in the amplification of lung injury. The research focuses on how lung infections induce widespread lung vascular endothelial injury through a cycle of endothelial barrier breakdown and inflammatory cell influx. The project...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $562,733 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop small molecule therapeutics for heart failure through reduction in tristetraprolin activity and improvement of cardiac metabolism. The project runs through May 31, 2027, with work performed in Tucson, Arizona. The research targets tristetraprolin, a zinc finger protein that regulates fatty acid uptake and oxidation...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $783,885 for Project Grant R01HL181589 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research on the role of NTRK2 isoforms in alveolar injury and repair related to bronchopulmonary dysplasia (BPD), a chronic lung disease affecting approximately 10,000 premature infants annually in the United States. The research employs multiomic profiling...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $726,242 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize the cellular and molecular role of GATA4 in bicuspid aortic valve disease. The project, R01HL183091, runs through May 31, 2030, with place of performance in Tucson, Arizona. The award funds three research aims. Aim 1 comprehensively characterizes a GATA4S379G mouse model of bicuspid aortic valve disease,...